Equities Analysts Offer Predictions for SRPT Q2 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at Zacks Research increased their Q2 2025 EPS estimates for shares of Sarepta Therapeutics in a research note issued on Monday, October 21st. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $2.09 for the quarter, up from their prior forecast of $2.08. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.45 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q3 2025 earnings at $2.10 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $8.17 EPS and Q1 2026 earnings at $2.80 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. Sarepta Therapeutics’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.27) EPS.

SRPT has been the subject of several other research reports. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 14th. UBS Group boosted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and decreased their price objective for the company from $185.00 to $179.00 in a report on Thursday, August 8th. Finally, Piper Sandler dropped their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $132.02 on Wednesday. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The firm has a market capitalization of $12.48 billion, a price-to-earnings ratio of 1,200.18 and a beta of 0.82. The business has a 50 day simple moving average of $128.78 and a 200 day simple moving average of $132.40.

Insider Activity

In other news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently modified their holdings of SRPT. Nisa Investment Advisors LLC increased its stake in shares of Sarepta Therapeutics by 16.9% in the third quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 155 shares during the last quarter. Riggs Asset Managment Co. Inc. raised its stake in shares of Sarepta Therapeutics by 666.7% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 2,300 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 2,000 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in shares of Sarepta Therapeutics by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 11,035 shares of the biotechnology company’s stock valued at $1,378,000 after buying an additional 750 shares during the last quarter. PFG Investments LLC grew its stake in shares of Sarepta Therapeutics by 8.7% in the 3rd quarter. PFG Investments LLC now owns 26,674 shares of the biotechnology company’s stock valued at $3,331,000 after buying an additional 2,145 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Sarepta Therapeutics by 112.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,002 shares of the biotechnology company’s stock worth $747,000 after buying an additional 3,180 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.